glp 1 and covid 19 Could GLP-1 weight loss drugs treat long-haul COVID? Medscape | GLP-1 receptor agonists

A: MT-2 binds to four of the five known melanocortin receptor subtypes: MC1R (expressed on melanocytes and skin cells), MC3R (brain, gut, and immune tissue), MC4R (hypothalamus associated with energy homeostasis research), and MC5R (exocrine glands and immune tissue)

per week

In a randomized trial using PET-MRI to assess carotid plaque inflammation, semaglutide did not show a significant difference versus placebo on the prespecified primary plaque-inflammation endpointslikely influenced by low baseline inflammatory burden in a well-treated population. How to interpret this: Imaging studies like this are helpful for understanding mechanisms and terminology (e.g., atherosclerotic inflammation, PET-MRI plaque imaging), but they do not establish semaglutide as a direct vascular inflammation imaging reducer in general clinical use based on current evidence. 5) They Improve Kidney Outcomes in High-Risk Populations (Semaglutide) By improving glycemic control and metabolic stress, GLP-1 therapies can reduce kidney risk in susceptible patients

It is associated with telomerase activation and telomere maintenance, making it a key compound in anti-aging and circadian rhythm research